296 related articles for article (PubMed ID: 30692639)
21. Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma.
Tee AE; Ciampa OC; Wong M; Fletcher JI; Kamili A; Chen J; Ho N; Sun Y; Carter DR; Cheung BB; Marshall GM; Liu PY; Liu T
Int J Cancer; 2020 Oct; 147(7):1928-1938. PubMed ID: 32086952
[TBL] [Abstract][Full Text] [Related]
22. ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942.
Sava GP; Fan H; Fisher RA; Lusvarghi S; Pancholi S; Ambudkar SV; Martin LA; Charles Coombes R; Buluwela L; Ali S
Oncogene; 2020 Jan; 39(3):651-663. PubMed ID: 31530935
[TBL] [Abstract][Full Text] [Related]
23. THZ1 suppresses human non-small-cell lung cancer cells in vitro through interference with cancer metabolism.
Cheng ZJ; Miao DL; Su QY; Tang XL; Wang XL; Deng LB; Shi HD; Xin HB
Acta Pharmacol Sin; 2019 Jun; 40(6):814-822. PubMed ID: 30446732
[TBL] [Abstract][Full Text] [Related]
24. Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors.
Kalan S; Amat R; Schachter MM; Kwiatkowski N; Abraham BJ; Liang Y; Zhang T; Olson CM; Larochelle S; Young RA; Gray NS; Fisher RP
Cell Rep; 2017 Oct; 21(2):467-481. PubMed ID: 29020632
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer.
Li B; Ni Chonghaile T; Fan Y; Madden SF; Klinger R; O'Connor AE; Walsh L; O'Hurley G; Mallya Udupi G; Joseph J; Tarrant F; Conroy E; Gaber A; Chin SF; Bardwell HA; Provenzano E; Crown J; Dubois T; Linn S; Jirstrom K; Caldas C; O'Connor DP; Gallagher WM
Cancer Res; 2017 Jul; 77(14):3834-3845. PubMed ID: 28455421
[TBL] [Abstract][Full Text] [Related]
26. Super-Enhancers Promote Transcriptional Dysregulation in Nasopharyngeal Carcinoma.
Yuan J; Jiang YY; Mayakonda A; Huang M; Ding LW; Lin H; Yu F; Lu Y; Loh TKS; Chow M; Savage S; Tyner JW; Lin DC; Koeffler HP
Cancer Res; 2017 Dec; 77(23):6614-6626. PubMed ID: 28951465
[TBL] [Abstract][Full Text] [Related]
27. The covalent CDK7 inhibitor THZ1 enhances temsirolimus-induced cytotoxicity via autophagy suppression in human renal cell carcinoma.
Chow PM; Liu SH; Chang YW; Kuo KL; Lin WC; Huang KH
Cancer Lett; 2020 Feb; 471():27-37. PubMed ID: 31812697
[TBL] [Abstract][Full Text] [Related]
28. Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome.
Wei Y; Li C; Bian H; Qian W; Jin K; Xu T; Guo X; Lu X; Su F
Mol Cancer; 2021 Jan; 20(1):5. PubMed ID: 33397398
[TBL] [Abstract][Full Text] [Related]
29. Antitumor effects of a covalent cyclin-dependent kinase 7 inhibitor in colorectal cancer.
Wang J; Li Z; Mei H; Zhang D; Wu G; Zhang T; Lin Z
Anticancer Drugs; 2019 Jun; 30(5):466-474. PubMed ID: 30694816
[TBL] [Abstract][Full Text] [Related]
30. Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma.
Cao X; Dang L; Zheng X; Lu Y; Lu Y; Ji R; Zhang T; Ruan X; Zhi J; Hou X; Yi X; Li MJ; Gu T; Gao M; Zhang L; Chen Y
Thyroid; 2019 Jun; 29(6):809-823. PubMed ID: 30924726
[No Abstract] [Full Text] [Related]
31. Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma.
Jiang YY; Lin DC; Mayakonda A; Hazawa M; Ding LW; Chien WW; Xu L; Chen Y; Xiao JF; Senapedis W; Baloglu E; Kanojia D; Shang L; Xu X; Yang H; Tyner JW; Wang MR; Koeffler HP
Gut; 2017 Aug; 66(8):1358-1368. PubMed ID: 27196599
[TBL] [Abstract][Full Text] [Related]
32. THZ1 Reveals Roles for Cdk7 in Co-transcriptional Capping and Pausing.
Nilson KA; Guo J; Turek ME; Brogie JE; Delaney E; Luse DS; Price DH
Mol Cell; 2015 Aug; 59(4):576-87. PubMed ID: 26257281
[TBL] [Abstract][Full Text] [Related]
33. Suppression of Angiogenesis by Targeting Cyclin-Dependent Kinase 7 in Human Umbilical Vein Endothelial Cells and Renal Cell Carcinoma: An In Vitro and In Vivo Study.
Shi CS; Kuo KL; Chen MS; Chow PM; Liu SH; Chang YW; Lin WC; Liao SM; Hsu CH; Hsu FS; Chang HC; Huang KH
Cells; 2019 Nov; 8(11):. PubMed ID: 31752390
[TBL] [Abstract][Full Text] [Related]
34. Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer effects in head and neck squamous cell carcinoma.
Zhang W; Ge H; Jiang Y; Huang R; Wu Y; Wang D; Guo S; Li S; Wang Y; Jiang H; Cheng J
Cancer Lett; 2020 Jan; 469():510-523. PubMed ID: 31765738
[TBL] [Abstract][Full Text] [Related]
35. High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma.
Eliades P; Abraham BJ; Ji Z; Miller DM; Christensen CL; Kwiatkowski N; Kumar R; Njauw CN; Taylor M; Miao B; Zhang T; Wong KK; Gray NS; Young RA; Tsao H
J Invest Dermatol; 2018 Jul; 138(7):1582-1590. PubMed ID: 29408204
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of the CDK7 Inhibitor on EMT-Associated Resistance to 3rd Generation EGFR-TKIs in Non-Small Cell Lung Cancer Cell Lines.
Ji W; Choi YJ; Kang MH; Sung KJ; Kim DH; Jung S; Choi CM; Lee JC; Rho JK
Cells; 2020 Dec; 9(12):. PubMed ID: 33287368
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
38. Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13.
Zeng M; Kwiatkowski NP; Zhang T; Nabet B; Xu M; Liang Y; Quan C; Wang J; Hao M; Palakurthi S; Zhou S; Zeng Q; Kirschmeier PT; Meghani K; Leggett AL; Qi J; Shapiro GI; Liu JF; Matulonis UA; Lin CY; Konstantinopoulos PA; Gray NS
Elife; 2018 Nov; 7():. PubMed ID: 30422115
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic Targeting of CDK7 Suppresses Tumor Progression in Intrahepatic Cholangiocarcinoma.
Chen HD; Huang CS; Xu QC; Li F; Huang XT; Wang JQ; Li SJ; Zhao W; Yin XY
Int J Biol Sci; 2020; 16(7):1207-1217. PubMed ID: 32174795
[TBL] [Abstract][Full Text] [Related]
40. Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast Cancer.
Guarducci C; Nardone A; Russo D; Nagy Z; Heraud C; Grinshpun A; Zhang Q; Freelander A; Leventhal MJ; Feit A; Cohen Feit G; Feiglin A; Liu W; Hermida-Prado F; Kesten N; Ma W; De Angelis C; Morlando A; O'Donnell M; Naumenko S; Huang S; Nguyen QD; Huang Y; Malorni L; Bergholz JS; Zhao JJ; Fraenkel E; Lim E; Schiff R; Shapiro GI; Jeselsohn R
Clin Cancer Res; 2024 May; 30(9):1889-1905. PubMed ID: 38381406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
